Jefferies Remains Positive on Neurocrine Bio. (NBIX) and NBI-98854 Despite Problems With Phase 2 Study Site

Jefferies reiterated its Buy-rating and $13 price target on Neurocrine Bio. (NASDAQ: NBIX) following mixed data for NBI-98854 (854) Phase 2 study, in which one site appeared to be an outlier in its scoring of study subjects.

The firm comments, "While we are usually skeptics of post-hoc analyses excluding data, several factors lead us to accept NBIX's hypothesis, and we believe the data support efficacy for 854. Although not in our valuation, 854 could lead to upside, and we are buyers, especially on any price weakness."

For an analyst ratings summary and ratings history on Neurocrine Bio. click here. For more ratings news on Neurocrine Bio. click here.

Shares of Neurocrine Bio. closed at $8.99 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Cummins (CMI) PT Lowered to $675 at Jefferies
• Intchains Group Ltd (ICG) PT Lowered to $2 at Benchmark Following 1H Results
• DA Davidson Starts Comfort Systems USA (FIX) at Buy